Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

globenewswire.com
NVS Novartis's 225Ac-PSMA-617 is mentioned as an emerging therapy driving growth in the metastatic prostate cancer market. The company is also listed as a key RLT company. TLX Telix Pharmaceuticals' TLX591 is highlighted as a leading radioligand antibody-drug conjugate targeting PSMA, with ongoing Phase III trials. The company is repeatedly mentioned as a key player in radioligand and PSMA-targeted therapies. PFE Pfizer's Mevrometostat (PF-06821497) is identified as a potent inhibitor targeting EZH2 for prostate cancer, aiming to suppress tumor growth. The company is also listed as a key mCSPC company. EXEL Exelixis' Cabozantinib (CABOMETYX, XL184) is mentioned as a multi-targeted tyrosine kinase inhibitor with a planned sNDA filing. The company is also listed as a key metastatic castration-resistant prostate cancer company. LLY Eli Lilly and Company is mentioned as a partner for Lu-PNT2002 and is listed as a key company in radioligand therapies and metastatic castration-resistant prostate cancer markets. XNCR Xencor's Vudalimab (XmAb-20717) is listed as an emerging drug, and the company is mentioned in the context of metastatic castration-resistant prostate cancer, but no specific sentiment is conveyed. BTE Blue Earth Therapeutics' 177Lu-rhPSMA-10.1 is listed as an emerging drug, but no further details or sentiment are provided. ORIC ORIC Pharmaceuticals' ORIC-944 is listed as an emerging drug, and the company is mentioned in the context of the pipeline, but no specific sentiment is conveyed. MRK Merck's Opevesostat (MK-5684; ODM-208) is listed as an emerging drug, and the company is mentioned in the context of mCSPC and mCRPC, but no specific sentiment is conveyed. ABBV AbbVie is mentioned in the context of the metastatic prostate cancer pipeline, but no specific drug or sentiment is detailed. BMY Bristol-Myers Squibb is mentioned in the context of the metastatic prostate cancer pipeline and mCRPC, but no specific drug or sentiment is detailed. AZN AstraZeneca is mentioned in the context of the metastatic prostate cancer pipeline, RLT, and mCRPC/mCSPC markets, but no specific drug or sentiment is detailed. AMGN Amgen is not explicitly mentioned in the article.

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight New York, USA, June 10, 2026 (GLOBE NEWSWIRE) -- Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway inhibitors continue to dominate across mHSPC and mCRPC settings, the emergence of novel therapies such as 225Ac‑PSMA‑617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma, and Takeda), and others is significantly reshaping the treatment paradigm.

Recently published Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Metastatic Prostate Cancer Market Summary

Discover how fast will the metastatic prostate cancer market grow in the US, EU4, UK, and Japan @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Key Factors Driving the Growth of the Metastatic Prostate Cancer Market

According to Aparna Thakur, project manager of forecasting at DelveInsight, the late-stage pipeline, including next-generation PARP inhibitors, AKT inhibitors, PSMA-targeted therapies, and novel AR degraders, is expected to intensify market competition and further expand precision treatment opportunities during the forecast period.

Metastatic Prostate Cancer Market Analysis

Learn more about which drugs are losing market share @ Metastatic Prostate Cancer Treatment Market

Metastatic Prostate Cancer Competitive Landscape

Some of the metastatic prostate cancer drugs under development include 225Ac‑PSMA‑617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma and Takeda), PT-112 (Promontory Therapeutics), Vudalimab (XmAb-20717) (Xencor), 177Lu-rhPSMA-10.1 (Blue Earth Therapeutics), ORIC-944 (ORIC Pharmaceuticals), 177Lu-PSMA-I&T (Curium), FPI-2265 (Fusion Pharmaceuticals), Opevesostat (MK-5684; ODM-208) (Merck and Orion), KPG-121 (Kangpu Biopharmaceuticals), Lu-PNT2002 (Lantheus and Eli Lilly and Company), and others.

Telix's TLX591 is a leading radioligand antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA). The ProstACT clinical program, including the Phase II/III ProstACT GLOBAL study, is assessing the treatment's efficacy and safety across various stages of prostate cancer, ranging from initial recurrence to advanced metastatic disease. At present, TLX591 is undergoing evaluation in the Phase III ProstACT Global trial, with interim results from Part I expected in the near future.

Pfizer’s Mevrometostat is a highly potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2). By targeting EZH2, a key driver of prostate cancer cell proliferation, the therapy aims to suppress tumor growth. Its mechanism involves reducing levels of H3K27Me3, a protein marker associated with EZH2 activity and cancer progression.

Curium’s 177Lu-PSMA-I&T is a radiopharmaceutical therapy developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It selectively binds to PSMA-positive tumor cells and delivers beta-radiation directly to cancerous tissue, leading to targeted cell destruction. Curium continues to support the ongoing pivotal ECLIPSE trial through uninterrupted clinical supply and patient enrollment activities.

Exelixis' lead therapeutic candidate, Cabozantinib, is a multi-targeted tyrosine kinase inhibitor that blocks several signaling pathways, including MET, AXL, VEGF receptors, and RET. The company had planned to file a supplemental New Drug Application (sNDA) with the U.S. FDA for cabozantinib in mCRPC during late 2024; however, no further updates regarding the submission or regulatory progress have been announced to date.

The anticipated launch of these emerging metastatic prostate cancer therapies are poised to transform the metastatic prostate cancer market landscape in the coming years. As these cutting-edge metastatic prostate cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the metastatic prostate cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about how much revenue is generated by radioligand therapies, visit @ Metastatic Prostate Cancer Medication

Recent Developments in the Metastatic Prostate Cancer Market

What is Metastatic Prostate Cancer?

Metastatic prostate cancer is an advanced stage of prostate cancer in which malignant cells spread beyond the prostate gland to other parts of the body, most commonly the bones, lymph nodes, liver, or lungs. This progression occurs when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system, establishing new tumors in distant organs. Patients with metastatic prostate cancer may experience symptoms such as bone pain, fatigue, urinary difficulties, weight loss, and reduced quality of life. Although the disease is generally not curable at this stage, significant advances in treatment, including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors, chemotherapy, radioligand therapies, and targeted treatments, have improved survival outcomes and disease management.

Metastatic Prostate Cancer Epidemiology Segmentation

The metastatic prostate cancer epidemiology section provides insights into the historical and current metastatic prostate cancer patient pool and forecasted trends for the leading markets. Based on DelveInsight's assessment in 2025, the US had ~3.8 million prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2026−2036).

The metastatic prostate cancer market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand which companies dominate the mCRPC market @ Metastatic Prostate Cancer Treatment Options

Scope of the Metastatic Prostate Cancer Market Report

Discover more about late-stage prostate cancer pipeline drugs @ Metastatic Prostate Cancer Clinical Trials

Table of Contents

Related Reports

Metastatic Prostate Cancer Clinical Trial Analysis

Metastatic Prostate Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic prostate cancer companies, including Telix Pharmaceuticals, Candel Therapeutics, Astellas Pharma, ORIC Pharmaceuticals, Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Geode Therapeutics Inc., Cullgen, AstraZeneca, TYK Medicines, Inc., K36 Therapeutics, Inc., Bristol-Myers Squibb, Kyntra Bio, ARTBIO Inc., Acerand Therapeutics, Janux Therapeutics, Evopoint Biosciences Inc., AbbVie, Arsenal Biosciences, Inc., Fusion Pharmaceuticals Inc., and others.

Radioligand Therapies Market

Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others.

PSMA-targeted Therapy Market

PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including Lantheus, Telix Pharmaceuticals, Novartis, and others.

Metastatic Castration-Resistant Prostate Cancer Market

Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic castration-resistant prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others.

Metastatic Castration-Sensitive Prostate Cancer Market

Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.